

## Financial Tear Sheet

### Corporate Profile

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

*Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.*

### Stock Performance

#### ARAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$4.45</b>
Change (%)	0.00 (0.00%)
Volume	18,946
52 Week Low	\$3.85
Market Cap	\$369,354,299
Rolling EPS	-0.39
PE Ratio	N/A
Shares Outstanding	83,000,966

Data as of Jul 26, 2017 9:50 a.m. ET



## Press Releases

Jul 20, 2017 - 7:30 a.m.

New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers

---

Jul 17, 2017 - 4:06 p.m.

Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results

---

Jul 11, 2017 - 7:30 a.m.

Neuro Spinal Hospital in Dubai to Acquire Accuray CyberKnife® and Radixact™ Systems

---

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	
Jul 17, 2017	8-K	
Jul 3, 2017	4	
Jul 3, 2017	4	
Jul 3, 2017	4	

---

## Corporate Governance

Joshua H. Levine	President and Chief Executive Officer
LIONEL HADJADJEB	SENIOR VICE PRESIDENT, CHIEF COMMERCIAL OFFICER
Kevin Waters	Senior Vice President, Chief Financial Officer
Darl S. Moreland	Senior Vice President, Regulatory, Quality and Compliance
Alaleh Nouri	Senior Vice President, General Counsel and Corporate Secretary
Andy Kirkpatrick	Senior Vice President, Global Operations and Corporate Development

Data provided by Nasdaq. Minimum 15 minutes delayed.

---

© 2007 - 2017 Accuray Incorporated. All Rights Reserved.